Vivid T8, Vivid T9
GE Medical Systems Ultrasound and Primary Care Diagnostics, • Radiology • 07/18/2022
Device Purpose
The Vivid T8/T9 are advanced diagnostic ultrasound systems designed for comprehensive imaging, primarily cardiac, utilizing a range of transducers and imaging modes, now enhanced with AI-driven tools for automated cardiac function assessment. These systems aim to improve diagnostic capabilities and workflow efficiency through updated software, expanded clinical applications including thoracic/pleural imaging, and new transducer options.
Summary
The Vivid T8 and Vivid T9 are mobile diagnostic ultrasound systems primarily intended for cardiac imaging and analysis, with additional capabilities for vascular and general radiology applications. These systems feature a console with a control panel, a color LCD touch panel, an LCD display monitor, and support various electronic array transducers (linear, curved, sector/phased, matrix, dual array, and dedicated CW). The user interface includes a 21.5-inch LCD monitor and a 10.1-inch multi-touch panel with an alpha-numeric keyboard. Key differences between the models include the Vivid T9's height-adjustable control panel and standard flexible monitor arm, whereas the Vivid T8 has a fixed control panel with an optional flexible arm; the T9 offers full functionality and transducer support. Both systems utilize digital acquisition, processing, analysis, and display capabilities, and support network connectivity. The technology underlying the Vivid T8/T9 relies on established ultrasound principles, offering modes such as B, M, PW/CW Doppler, Color Doppler, Power Doppler, and Harmonic Imaging. Clinical applications have been expanded to include Thoracic/Pleural imaging and an independent listing for Urology. Significant software enhancements include workflow tools like Pre-Post Compare and Image Spooler, and AI-driven features: Easy Auto EF and Easy AFI LV, which utilize an AI Auto ROI algorithm for automated cardiac measurements with reported accuracy around 92%. Other additions are a Spline Tool for measurements, Strain Elastography, Imaging Insights Data Collection, and Probe Check. The systems also support new transducers (M5Sc-RS, L4-20t-RS, C1-5-RS) with expanded application compatibility, including biopsy guides for select models.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the 'AI Auto ROI' algorithm in Easy Auto EF and Easy AFI LV account for variations in cardiac anatomy and image quality across diverse patient populations not extensively represented in the initial test datasets (e.g., specific ethnicities, body habitus, or rare cardiac pathologies)?; What is the quantifiable impact of the new workflow enhancement tools (Pre-Post Compare, Image Spooler) and AI features (Easy Auto EF, Easy AFI LV) on examination time and inter-observer variability in clinical practice?; Given the addition of the Thoracic/Pleural application, what specific image optimization presets or transducer features are tailored for improved lung and pleural visualization compared to general abdominal settings?; Could the 'Imaging Insights Data Collection Support' feature be leveraged for further AI model refinement or to identify clinical best practices in using the Vivid T8/T9 systems?; What are the specific performance characteristics (e.g., resolution, penetration) of the newly added transducers (M5Sc-RS, L4-20t-RS, C1-5-RS) in their respective intended applications, particularly for the Thoracic/Pleural and newly listed Urology applications?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly